Clinical Trials Logo

Candidemia clinical trials

View clinical trials related to Candidemia.

Filter by:

NCT ID: NCT06194201 Recruiting - Clinical trials for Patients With Candidemia and/or Invasive Candidiasis

A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis

Start date: April 27, 2024
Phase: Phase 2
Study type: Interventional

The Purpose of this study is to evaluate the efficacy and safety of intravenous HRS9432 in patients with candidemia and/or invasive candidiasis

NCT ID: NCT05763251 Recruiting - Clinical trials for Invasive Candidiasis

Comparison of Uncomplicated Candidemia Therapy Duration in Children

COUNT
Start date: September 8, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare antifungal therapy duration in pediatric uncomplicated candidemia. The specific aims are: - Compare the desirability of outcome ranking in children with uncomplicated candidemia randomized to 7 additional days of antifungal therapy (standard-course) versus no additional antifungal therapy (short-course) after already receiving 7 days of echinocandin therapy. - Compare the 14-day desirability of outcome measure for subjects with a negative and those with a positive T2Candida® biomarker at day 7 of therapy within randomized groups. Participants meeting eligibility criteria will be approached and consented between day 5 and 7 of primary systemic antifungal therapy. On day 7 of primary systemic antifungal therapy, inclusion and exclusion criteria will again be reviewed for consented patients and those still eligible will be randomized 1:1 to the two study arms. Researchers will compare no additional antifungal therapy (short-course) versus 7 additional days of systemic antifungal therapy (standard-course) in pediatric patients with uncomplicated candidemia who have already received 7 days of primary systemic antifungal therapy to see if shorter durations are as effective as longer durations in treating uncomplicated candidemia.

NCT ID: NCT05720728 Completed - Candida Infection Clinical Trials

Research of New Serological Markers for the Diagnosis and Monitoring of Candidaemia in Hospitalized Patients

2419
Start date: May 14, 2019
Phase:
Study type: Observational

Bloodstream infections due to Candida spp remain a serious medical challenge because of their high incidence and poor outcome. Diagnosis and monitoring of patients are still problematic, hindering efficient clinical management of the disease. The invastigators propose here to perform a retrospective study in a clinically well-characterized candidemic patient, with the goal of recognizing host immunological factors and virulence-associated fungal molecules relevant in the onset and evolution of infection. The researchers' ultimate goal is to identify new diagnostic and/or prognostic benchmarks useful in clinical settings. By combining serologic and immunologic expertise with clinical expertise, the research team has real potential to generate new markers of host pathogenesis and immune response in candidemia and to inform prospective clinical trials to control this terrible disease

NCT ID: NCT05421858 Not yet recruiting - Candidemia Clinical Trials

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis

Start date: July 15, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Fosmanogepix) for the potential treatment of candidemia and/or invasive candidiasis, a life-threatening fungal infection caused by several species of yeast called Candida. The study is seeking patients who have a diagnosis of candidemia and / or invasive candidiasis. Two-thirds of all patients will receive the study medication fosmanogepix Intravenous (IV) infusion followed by optional fosmanogepix tablets. One-third of all patients will receive a standard of care regimen of caspofungin Intravenous (IV) infusion followed by optional fluconazole capsules. Fosmaogepix or caspofungin will first be given as an Intravenous (IV) infusion directly into a vein in the arm each day at the study clinic. Fosmaogepix tablets or fluconazole capsules will be taken orally by mouth daily either at the study clinic, or at home if patients are well enough to be discharged from the hospital. We will compare the experience of patients receiving fosmanogepix to those receiving caspofungin/ fluconazole. This will help us determine if fosmanogepix is safe and effective. Patients will continue treatment for a maximum of 6 weeks depending on whether the infection has cleared and whether the symptoms related to the infection has improved. During this time, they will have study visits for up to 10 times. There will also be a follow-up visit 6 weeks after the study treatment was stopped.

NCT ID: NCT05385107 Completed - Clinical trials for The Value of Procalcitonin in Patients With Suspected Candidemia

Value of PCT When Diagnosing Candidemia

Start date: April 1, 2010
Phase:
Study type: Observational

This study is a retrospective analysis to identify and compare the shift in inflammatory biomarkers in ICU patients immediately before and after the first identification of candidemia.

NCT ID: NCT05178862 Suspended - Candidemia Clinical Trials

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

MARIO
Start date: August 3, 2022
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized, double-blind study of two treatment regimens for invasive candidiasis included candidemia. Subjects will receive intravenous echinocandin followed by oral ibrexafungerp (SCY-078) vs intravenous echinocandin followed by oral fluconazole.

NCT ID: NCT04979052 Recruiting - Candidemia Clinical Trials

Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia

Start date: March 31, 2022
Phase: Phase 2
Study type: Interventional

A multi-center open label adaptive randomized interventional phase 2 study to evaluate safety and efficacy of rIFN-y treatment in patiens with candidemia.

NCT ID: NCT04368559 Recruiting - Fungal Infection Clinical Trials

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

ReSPECT
Start date: May 11, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the prevention of invasive fungal diseases when compared to the standard antimicrobial regimen.

NCT ID: NCT04148287 Completed - Candidemia Clinical Trials

An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris

APEX
Start date: December 13, 2019
Phase: Phase 2
Study type: Interventional

This is a multicenter, open-label, single arm study to evaluate the efficacy and safety of APX001 for the treatment of candidemia and/or invasive candidiasis caused by C. auris in patients aged 18 years and over with limited antifungal treatment options.

NCT ID: NCT04147975 Recruiting - Bacteremia Clinical Trials

Assessment of Assay for Rapid Identification of Bloodstream Infections From Whole Blood

Start date: October 1, 2019
Phase:
Study type: Observational

The purpose of this study is to assess the effectiveness of RaPID/BSI by testing its performance compared to blood cultures collected prospectively from consented subjects.